{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:56:26Z","timestamp":1787756186728,"version":"build-2784847793"},"reference-count":46,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has demonstrated its potential as a curative option for patients with r\/r lymphoma. With the introduction of post-transplant cyclophosphamide-based (PTCY) graft-versus-host disease (GvHD) prophylaxis, allo-HCT using haploidentical related donors (Haplo-HSCT) has emerged as a valuable alternative for patients without an available HLA-matched donor. In this study, we compared intermediate and long-term outcomes between Haplo-HSCT and HLA-matched related donor (MRD) and unrelated donor (URD) transplantations in 16 matched pairs using age, disease status, lymphoma classification and performance status as matching criteria. Of note, 88% of patients in each group presented with active disease at the time of conditioning. After a median follow-up of &gt;10 years, 10-year overall and progression-free survival and non-relapse mortality incidence after Haplo-HSCT were 31%, 25% and 38%, respectively, and did not differ compared to the values observed in MRD-HSCT and URD-HSCT. A remarkable lower incidence of acute GvHD \u2265 II and moderate and severe chronic GvHD was observed after Haplo-HSCT compared to MRD-HSCT (50%\/50%, p = 0.03\/0.03) and URD-HSCT (44%\/38%, p = 0.04\/0.08), resulting in slightly higher 10-year GvHD-free and relapse-free survival (25%) and chronic GvHD-free and relapse-free survival (25%) in the Haplo-HSCT group. In conclusion, Haplo-HSCT is an effective treatment in patients with non-remission NHL. Given its advantage of immediate availability, haploidentical donors should be preferably used in patients with progressive disease lacking an HLA-matched related donor.<\/jats:p>","DOI":"10.3390\/cancers15215246","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T12:48:31Z","timestamp":1698756511000},"page":"5246","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma\u2014A Matched-Pair Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Sarah","family":"Haebe","sequence":"first","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fraccaroli","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Stauffer","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Prevalsek","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Zoellner","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Drolle","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Stemmler","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Ludwig-Maximilians-University (LMU) University Hospital Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"Canals","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","article-title":"Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients","volume":"22","author":"Fenske","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2010-12-324392","article-title":"(9)(0)Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma","volume":"118","author":"Gopal","year":"2011","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.328","article-title":"Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma","volume":"50","author":"Zoellner","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/bmt.2014.4","article-title":"Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma","volume":"49","author":"Avivi","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41375-023-01924-x","article-title":"Allogeneic hematopoietic stem cell transplantation for NK\/T-cell lymphoma: An international collaborative analysis","volume":"37","author":"Berning","year":"2023","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/s41409-019-0465-9","article-title":"The EBMT activity survey report 2017: A focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies","volume":"54","author":"Passweg","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41409-019-0583-4","article-title":"Haploidentical stem cell transplantation for patients with lymphoma: A position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation","volume":"55","author":"Dietrich","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"Use of haploidentical stem cell transplantation continues to increase: The 2015 European Society for Blood and Marrow Transplant activity survey report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","article-title":"Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: Results of a prospective phase II trial","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2014.09.009","article-title":"\u201cNo donor\u201d? Consider a haploidentical transplant","volume":"29","author":"Ciurea","year":"2015","journal-title":"Blood Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs. HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/leu.2016.125","article-title":"Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: A registry study by the European society for blood and marrow transplantation","volume":"30","author":"Dietrich","year":"2016","journal-title":"Leukemia"},{"key":"ref_22","first-page":"2086","article-title":"Sequential Conditioning with Thiotepa in T-Cell Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematological Malignancies: Comparison with Matched Related, Haplo-Mismatched and Unrelated Donors","volume":"30","author":"Dulery","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs. matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/bloodadvances.2019000614","article-title":"HLA-haploidentical vs. matched-sibling hematopoietic cell transplantation: A systematic review and meta-analysis","volume":"3","author":"Meybodi","year":"2019","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ajh.25281","article-title":"Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed\/refractory AML\/MDS","volume":"93","author":"Fraccaroli","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00277-019-03593-2","article-title":"Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis","volume":"98","author":"Doppelhammer","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: Working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","unstructured":"Center for International Blood and Marrow Transplant Research (2023, September 15). CIBMTR Forms Manual: 100 Days Post-HSCT Data Form 2100. Available online: http:\/\/www.cibmtr.org\/DataManagement\/TrainingReference\/Manuals\/DataManagement\/Documents."},{"key":"ref_30","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","article-title":"Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: Incidence in the context of immune recovery in two different transplantation settings","volume":"94","author":"Tischer","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.bbmt.2019.02.002","article-title":"Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma","volume":"25","author":"Saini","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Abramson, H.N. (2018). Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201810.0577.v1"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Mariotti, J., Bramanti, S., Santoro, A., and Castagna, L. (2020). Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113589"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.bbmt.2015.07.012","article-title":"Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors","volume":"21","author":"Kanakry","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs. matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"184.e181","DOI":"10.1016\/j.jtct.2022.11.028","article-title":"Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas","volume":"29","author":"Mussetti","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?","volume":"26","author":"Dreger","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant. Cell Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/21\/5246\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:14Z","timestamp":1760130914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/21\/5246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":46,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["cancers15215246"],"URL":"https:\/\/doi.org\/10.3390\/cancers15215246","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]}}}